Recovery of the response to biological treatments using narrow band ultraviolet-B in patients with moderate to severe psoriasis: a retrospective study of 17 patients

Authors

  • Isabel Belinchón,

    Corresponding author
    1. Department of Dermatology, Hospital General Universitario de Alicante, Alicante, Spain
    2. Department of Clinical Medicine, Universidad Miguel Hernández de Elche, Alicante, Spain
    • Correspondence:

      Dr Isabel Belinchón, PhD, MD, Department of Dermatology, Hospital General Universitario de Alicante, Av Pintor Baeza 12, 03010 Alicante, Spain.

      Tel: +34 965933024

      Fax: +34 965913688

      e-mail: belinchon_isa@gva.es

    Search for more papers by this author
  • María Paloma Arribas,

    1. Department of Dermatology, Hospital General Universitario de Alicante, Alicante, Spain
    Search for more papers by this author
  • Pilar Soro,

    1. Department of Dermatology, Hospital General Universitario de Alicante, Alicante, Spain
    Search for more papers by this author
  • Isabel Betlloch

    1. Department of Dermatology, Hospital General Universitario de Alicante, Alicante, Spain
    2. Department of Clinical Medicine, Universidad Miguel Hernández de Elche, Alicante, Spain
    Search for more papers by this author

  • Funding:

    No funding sources has supported this work.

  • Conflicts of interest: I. Belinchón has served as a consultant for Pfizer-Wyeth; Janssen Pharmaceuticals Inc, and MSD, and as a speaker for Abbott-Abbvie, Pfizer-Wyeth, Janssen Pharmaceuticals Inc and MSD MP Arribas, P Soro and I Betlloch declare that no have any potential conflict of interest.

Summary

Background/Purpose

Biological therapy has demonstrated a very satisfactory anti-psoriatic effect; however, the loss of response with time has been reported.

Objective

To evaluate the efficacy of the narrow band ultraviolet-B phototherapy (NB-UVB) as a rescue in patients with moderate to severe psoriasis who have lost efficacy in their biological treatment.

Methods

A retrospective chart review study was conducted on patients with moderate to severe psoriasis receiving treatment with a biologic, with a good initial response that subsequently had lost efficacy. All the patients received combined treatment with NB-UVB.

Results

Seventeen patients were included, with a mean age of 44 years. The biologics were: 8 etanercept, 4 adalimumab, 3 ustekinumab, 1 efalizumab, and 1 infliximab. The mean NB-UVB sessions was 25 (7–48 sessions), with a mean accumulated dose of 31.12 J/cm2 (5.2–94.6 J/cm2). Sixteen patients had the following results: 44% PASI 90–100, 31.3% PASI 75–89, and 25% PASI 50–74 response.

Conclusion

According to this study on clinical practice, it could be considered that the use of NB-UVB along with biological drugs that have lost efficacy in controlling moderate to severe psoriasis in adults could contribute to the recovery of the initial response.

Ancillary